The estimated Net Worth of Frank Yocca is at least 3.75 百万$ dollars as of 14 June 2024. Frank Yocca owns over 1,083 units of BioXcel Therapeutics Inc stock worth over 7,615$ and over the last 7 years he sold BTAI stock worth over 3,092,700$. In addition, he makes 654,408$ as Chief Scientific Officer at BioXcel Therapeutics Inc.
Frank has made over 15 trades of the BioXcel Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,083 units of BTAI stock worth 596$ on 14 June 2024.
The largest trade he's ever made was exercising 80,000 units of BioXcel Therapeutics Inc stock on 14 February 2020 worth over 32,800$. On average, Frank trades about 10,047 units every 107 days since 2018. As of 14 June 2024 he still owns at least 13,846 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Frank Yocca stock trades at the bottom of the page.
DR. Frank D. Yocca Ph.D. serves as Chief Scientific Officer of the Company. He was Senior Vice President, CNS R&D of BioXcel. From 2005 to 2015, Dr. Yocca held multiple leadership roles at AstraZeneca plc, including Vice President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, Strategy Unit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Prior to this he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this Dr. Yocca served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer's clinical candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of the Early and Late Discovery and Development Teams from 1984 to 2001. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology for St. John's University.
As the Chief Scientific Officer of BioXcel Therapeutics Inc, the total compensation of Frank Yocca at BioXcel Therapeutics Inc is 654,408$. There are 2 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of 1,968,930$.
Frank Yocca is 64, he's been the Chief Scientific Officer of BioXcel Therapeutics Inc since 2017. There are 1 older and 12 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
Frank's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over 63,244,788$ worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth 321,105$ . The most active insiders traders include Vimal Bio Xcel Holdings, In...、Vimal Mehta、Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 29,814$. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth 413$.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: